ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9

Contributed by: GlobeNewswire

Tags

Biotechnology

More Like This

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

PR Newswire associated0

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy

Jumpcode Genomics and Takara Bio USA Announce Global Patent Partnership

PR Newswire associated0

Okomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target Validation

Parse Biosciences Launches Certified Service Provider Program

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

From left to right: Dr. Kärt Tomberg, CEO & Co-Founder, Dr. Leopold Parts, CTO, Dr. Rebecca Godfrey, COO. (Photo credit: ExpressionEdits)

ExpressionEdits Raises $13M in Seed Funding to Advance Protein Expression Using AI-Driven Intronization Technology